Lineage Cell Therapeutics, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.1 million (-61.3% year over year) and diluted EPS of -$0.03. It usually reports 37–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-61.3%
|
1
+104.9%
|
-0.03
+76.9%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
+14.8%
|
-5
-16.3%
|
-0.03
-50.0%
|
|
Mar 5, 2026
64 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
7
+130.4%
|
1
+126.0%
|
0.00
+126.3%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
4
-2.6%
|
-30
-881.6%
|
-0.13
-550.0%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
+96.4%
|
-30
-428.9%
|
-0.13
-333.3%
|
|
May 13, 2025
43 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
+4.0%
|
-4
+36.7%
|
-0.02
+50.0%
|
|
Mar 10, 2025
69 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3
+37.4%
|
-3
+31.5%
|
-0.01
+54.5%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
4
+203.3%
|
-3
+57.3%
|
-0.02
+50.0%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LCTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 876343
- Former names
- BIOTIME INC (until Aug 8, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.